8-K current report · filed Oct 13, 2026

MESA LABORATORIES INC /CO/ (MLAB) 8-K Current Report: October 13, 2026

Item 2.05Item 7.01MLAB overview

Short answer

MESA LABORATORIES INC /CO/ (MLAB) filed an 8-K current report with the SEC on October 13, 2026 reporting Item 2.05 (Costs Associated with Exit or Disposal Activities), Item 7.01 (Regulation FD Disclosure). Approximately 40 positions eliminated, primarily in Clinical Genomics, signaling a narrower focus on pharmacogenomics, oncology and high-utilization accounts.

MESA LABORATORIES INC /CO/ 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.05 · Costs Associated with Exit or Disposal Activities

  • Approximately 40 positions eliminated, primarily in Clinical Genomics, signaling a narrower focus on pharmacogenomics, oncology and high-utilization accounts
  • Hamburg, Germany facility exit targeted for February 2027 lease expiration
  • Estimated pre-tax restructuring charges of $2.6 million to $3.4 million, primarily in fiscal 2027
  • Expected cash expenditures of $2.9 million to $3.7 million, substantially within 12 months
  • Program completion targeted by fiscal 2027-end, with certain international exits extending into first-half fiscal 2028

Item 7.01 · Regulation FD Disclosure

  • Press release announces Mesa Laboratories’ Restructuring Program
  • Exhibit 99.1 contains the program details, including expected scope and financial impact
  • Restructuring announcement may signal cost reductions, organizational changes, or near-term charges

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other MESA LABORATORIES INC /CO/ 8-K filings

Get the next MLAB 8-K as it lands

Follow MLAB for push alerts, or ask the research agent what this filing means.